Composition and Method for Treating Metabolic Disorders

Abstract

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

Description

FIELD OF THE INVENTION[0001]The present invention relates to synthesis of bromocriptine citrate, and to compositions and dosage forms containing bromocriptine citrate that provide increased stability and water solubility compared to prior art bromocriptine dosage forms. In another aspect, the invention relates to methods for using these compositions and dosage forms for the treatment of metabolic disorders including type 2 diabetes mellitus (T2DM).BACKGROUND OF THE INVENTION[0002]Diabetes, one of the most insidious of the major diseases, can strike suddenly or lie undiagnosed for years while attacking the blood vessels and nerves. Diabetics, as group, are far more often afflicted with blindness, heart disease, stroke, kidney disease, hearing loss, gangrene and impotence. The total costs of diagnosed diabetes were estimated by the American Diabetes Association to be $245 billion in 2012 alone, an increase of over 40% over a five-year period (compared to 2007) and a FIGURE that repres...

AI Technical Summary

Benefits of technology

The present patent provides bromocriptine citrate and methods for using it to treat metabolic disorders such as T2DM. The bromocriptine citrate can be administered as a pharmaceutical dosage form containing bromocriptine citrate and pharmaceutically acceptable excipients. The dosage form can be orally or parenterally administered. The patent also describes a method for therapeutically modifying and resetting the central circadian rhythm of dopaminergic activity of a vertebrate by administering bromocriptine citrate. The patent also mentions that other therapeutic regimes can be used in combination with bromocriptine citrate for the treatment of metabolic disorders. The technical effects of the patent include providing an effective treatment for metabolic disorders and providing a convenient and effective method for administering bromocriptine citrate.

Problems solved by technology

Diabetes adversely affects the way the body uses sugars and starches which, during digestion, are converted into glucose.

In type 2 diabetes (T2DM), the pancreas produces insulin, but the amount of insulin is insufficient, or less than fully effective due to cellular resistance, or both.

These result, as a consequence of the diabetic condition, in elevated levels of glucose in the blood, and prolonged high blood sugar which is indicative of a condition which will cause blood vessel and nerve damage.

Prior to the onset of diabetes, the pancreas of the obese are taxed to produce additional insulin, but eventually, perhaps over several years, insulin productivity falls and diabetes results.

For example, individuals suffering from T2DM often experience problems with several body organs and systems.

The disease is also associated with substantially increased risk for cardiovascular disease (CVD), the leading cause of death in type 2 diabetics.

However, subjects with MS have much greater risk of developing cardiovascular disease than subjects without the syndrome.

However, the mesylate salt of bromocriptine nevertheless exhibits very poor (in absolute terms) water solubility and is additionally very susceptible to water degradation, two properties that significantly limit the optimization of the stability of bromocriptine formulations and their use in clinical medicine.

As a result of the high susceptibility of the mesylate salt of bromocriptine to water degradation, the shelf life of the compound is limited in micro and macro environments that may contain water of any sort.

Bromocriptine mesylate is further susceptible to heat degradation, particularly in aqueous / water environments.

Additionally, as a direct result of the very poor water solubility of the mesylate salt of bromocriptine, this compound exhibits poor absorption across biological cellular membranes (e.g., epithelia).

Images